Last reviewed · How we verify

Topical Ketoprofen 10% Cream

Imprimis Pharmaceuticals, Inc. · Phase 3 active Small molecule

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.

Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application. Used for Topical treatment of musculoskeletal pain and inflammation, Localized joint and soft tissue pain.

At a glance

Generic nameTopical Ketoprofen 10% Cream
Also known asKetotransdel (TDLP-110)
SponsorImprimis Pharmaceuticals, Inc.
Drug classNSAID (nonsteroidal anti-inflammatory drug)
TargetCOX-1, COX-2
ModalitySmall molecule
Therapeutic areaPain Management / Rheumatology
PhasePhase 3

Mechanism of action

Ketoprofen blocks COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. When applied topically as a 10% cream, it delivers the drug directly to affected tissues, reducing systemic exposure compared to oral formulations. This localized anti-inflammatory and analgesic effect is used to treat musculoskeletal pain and inflammation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: